Logo

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Share this
Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Shots:

  • The P-III VANISH-303 evaluates ibrexafungerp vs PBO in patients with VVC & P-II DOVE studies assess ibrexafungerp vs fluconazole for the same indication. The results were published in America’s Clinical Infectious Diseases
  • In the P-III study- the therapy was superior in completely resolving signs & symptoms of VVC @10 Day (50.5% vs 28.6%); superior mycological eradication (49.5% vs 19.4%); symptom resolution was sustained & further increased (59.6% vs 44.9%). Post hoc analysis showed similar rates of clinical cure & improvement (54.8% & 63.4%)- respectively
  • In the P-II DOVE study- ibrexafungerp showed similar efficacy to SC @10 Day with sustained efficacy @25 Day follow-up- was well-tolerated

Click here ­to­ read full press release/ article | Ref: Scynexis | Image: Scynexis


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family